Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Trauner

Showing results (51-60 of 775) with videos related to

Pageof 78
Sort By:
Journal of Hepatology|October 17, 2021
A life with bile acids: Alan F. Hofmann (1931-2021)Dietrich Keppler, Ulrich Beuers, Michael Trauner
Transplantation|April 24, 2008
Ischemia and cholestasis: more than (just) the bile ducts!Martin Wagner, Gernot Zollner, Michael Trauner
Lipids in Health and Disease|January 27, 2007
Primary sclerosing cholangitis--the arteriosclerosis of the bile duct?Peter Fickert, Tarek Moustafa, Michael Trauner
Hepatology (Baltimore, Md.)|October 31, 2008
Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammationMartin Wagner, Gernot Zollner, Michael Trauner
Biochimica Et Biophysica Acta|October 28, 2009
Fatty liver and lipotoxicityMichael Trauner, Marco Arrese, Martin Wagner
Wiener Klinische Wochenschrift. Education|April 15, 2020
Katharina Staufer, Michael Trauner, Valentin Fuhrmann
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2025
ReplyThomas Reiberger, Nina Dominik, Michael Trauner
Clinics in Liver Disease|April 2, 2013
Nuclear receptors as drug targets in cholestatic liver diseasesEmina Halilbasic, Anna Baghdasaryan, Michael Trauner
Current Opinion in Critical Care|February 14, 2013
Hypoxic liver injury and cholestasis in critically ill patientsThomas Horvatits, Michael Trauner, Valentin Fuhrmann
Journal of Hepatology|March 7, 2025
Reply to "Pharmacological inhibition of ATGL as therapeutic approach for MASH: Far beyond the lipase suppressing role of ATGL inhibitors"Emmanuel Dauda Dixon, Thierry Claudel, Michael Trauner
Pageof 78

Showing results (51-60 of 775) with videos related to

Sort By:
Pageof 78
Journal of Hepatology|October 17, 2021
A life with bile acids: Alan F. Hofmann (1931-2021)Dietrich Keppler, Ulrich Beuers, Michael Trauner
Transplantation|April 24, 2008
Ischemia and cholestasis: more than (just) the bile ducts!Martin Wagner, Gernot Zollner, Michael Trauner
Lipids in Health and Disease|January 27, 2007
Primary sclerosing cholangitis--the arteriosclerosis of the bile duct?Peter Fickert, Tarek Moustafa, Michael Trauner
Hepatology (Baltimore, Md.)|October 31, 2008
Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammationMartin Wagner, Gernot Zollner, Michael Trauner
Biochimica Et Biophysica Acta|October 28, 2009
Fatty liver and lipotoxicityMichael Trauner, Marco Arrese, Martin Wagner
Wiener Klinische Wochenschrift. Education|April 15, 2020
Katharina Staufer, Michael Trauner, Valentin Fuhrmann
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2025
ReplyThomas Reiberger, Nina Dominik, Michael Trauner
Clinics in Liver Disease|April 2, 2013
Nuclear receptors as drug targets in cholestatic liver diseasesEmina Halilbasic, Anna Baghdasaryan, Michael Trauner
Current Opinion in Critical Care|February 14, 2013
Hypoxic liver injury and cholestasis in critically ill patientsThomas Horvatits, Michael Trauner, Valentin Fuhrmann
Journal of Hepatology|March 7, 2025
Reply to "Pharmacological inhibition of ATGL as therapeutic approach for MASH: Far beyond the lipase suppressing role of ATGL inhibitors"Emmanuel Dauda Dixon, Thierry Claudel, Michael Trauner
Pageof 78